Viking Therapeutics, Inc. (VKTX)
Viking Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company, specializing in the creation of novel treatments for metabolic and endocrine conditions. The company's leading investigational drug, VK2809, is an orally administered, tissue and receptor-selective agonist of the thyroid hormone receptor beta (TRß). This compound is currently progressing through Phase IIb clinical trials, targeting both non-alcoholic steatohepatitis (NASH) in biopsy-confirmed patients and non-alcoholic fatty liver disease (NAFLD). Viking's pipeline also features VK5211, an oral, non-steroidal selective androgen receptor modulator undergoing Phase II studies for individuals recuperating from non-elective hip fracture surgery. Additionally, VK0612, an oral drug candidate for type 2 diabetes, is poised to enter Phase IIb trials. The firm is also developing VK0214, another orally active, tissue and receptor-selective TRß agonist, specifically aimed at X-linked adrenoleukodystrophy. Founded in 2012, Viking Therapeutics is headquartered in San Diego, California.
Sector: Pharmaceutical Preparations
Industry: Biotechnology
Viking Therapeutics, Inc.
1-25 of 651 filings
Recent SEC filings with analysis
- 10-QViking Therapeutics reported a Q3 2026 net loss of $183.2 million ($1.55/share) versus $90.8 million a year ago, driven by a 126% nine-month jump in R&D spend…
- 8-KViking Therapeutics reported a Q3 2026 net loss of $183.2 million ($1.55 per share), roughly double the $90.8 million loss a year earlier, driven by R&D…
- 8-KViking Therapeutics entered into underwriting agreements on September 23, 2026 with Morgan Stanley and J.P.
- 424B5Viking Therapeutics priced a follow-on offering of 7,857,143 shares at $35.00 per share, raising $275 million gross (approximately $258.2 million net), with a…
- 424B5Viking Therapeutics priced a $225 million offering of 2.00% convertible senior notes due 2032, with a $33.75 million over-allotment option and estimated net…
- 424B5Viking Therapeutics filed a preliminary prospectus supplement for a registered offering of common stock, led by Morgan Stanley and J.P.
- 424B5Viking Therapeutics filed a preliminary 424B5 on September 23, 2026 to offer convertible senior notes due 2032, with a 30-day underwriter option for additional…